SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ridefelt Peter)
 

Sökning: WFRF:(Ridefelt Peter) > (2020-2024) > Interlaboratory var...

Interlaboratory variation for NT-proBNP among Swedish laboratories in an external quality program 2011-2021

Lundgren, Morgan (författare)
Uppsala universitet,Klinisk kemi
Ridefelt, Peter (författare)
Uppsala universitet,Klinisk kemi
Karlsson, Mathias (författare)
Equalis AB (External Quality Assurance in Laboratory Medicine in Sweden), Uppsala, Sweden
visa fler...
Norling, Anna (författare)
Equalis AB (External Quality Assurance in Laboratory Medicine in Sweden), Uppsala, Sweden
Larsson, Anders (författare)
Uppsala universitet,Klinisk kemi
visa färre...
 (creator_code:org_t)
2023-03-30
2023
Engelska.
Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter. - 1434-6621 .- 1437-4331. ; 61:9, s. 1643-1651
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objectives: NT-proBNP is frequently used for ruling out heart failure. Different cut-offs are used depending on the clinical context, e.g. an acute or chronic condition. Medical decision limits have been suggested at 125 and 300 ng/L or 400 ng/L in international guidelines. However, there is limited standardization between NT-proBNP methods and using the same blood sample might cause different treatment of patients.Methods: Data from the external quality assessment program for NT-proBNP from Equalis, Sweden, were extracted for the period 2011-2021, and categorized according to manufacturer. Manufacturer median NT-proBNP values were compared to total median values. CV% was calculated for each manufacturer and in comparison to different levels of NT-proBNP.Results: Roche was the most common method, and its median results were closest to the median consensus results. When looking at the total CV at NT-proBNP levels in the range of 0-500 ng/L, the total CV varied from 4 to 27%. During 2019-2021, Siemens (Immulite, Centaur, Atellica) yielded results 16-20% above the consensus median depending on sample level. Similarly, Abbott was 5-7% above, while Roche and Siemens Stratus were 1% respectively 6-10% below the consensus median.Conclusions: The introduction of new manufacturers and methods in 2017 have caused the agreement between manufacturers to decline. This highlights the need for a common calibrator and reference materials, particularly since medical decision limits in guidelines, e.g. European Society of Cardiology 2021, which are mostly based on Roche methods, do not take these method differences into account.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

brain
external quality assessment
heart failure
inter-laboratory variation
natriuretic peptide
standardization

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Lundgren, Morgan
Ridefelt, Peter
Karlsson, Mathia ...
Norling, Anna
Larsson, Anders
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Kardiologi
Artiklar i publikationen
Clinical Chemist ...
Av lärosätet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy